Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Widespread gene transfer to the retina is challenging as it requires vector systems to overcome physical and biochemical barriers to enter and diffuse throughout retinal tissue. We investigated whether exosome-associated adeno-associated virus, (exo-AAV) enabled broad retinal targeting following intravitreal (IVT) injection, as exosomes have been shown to traverse biological barriers and mediate widespread distribution upon systemic injection. We packaged an AAV genome encoding green fluorescent protein (GFP) into conventional AAV2 and exo-AAV2 vectors. Vectors were IVT injected into the eyes of adult mice. GFP expression was noninvasively monitored by fundus imaging and retinal expression was analyzed 4 weeks post-injection by qRT-PCR and histology. Exo-AAV2 outperformed conventional AAV2 in GFP expression based on fundus image analysis and qRT-PCR. Exo-AAV2 demonstrated deeper penetration in the retina, efficiently reaching the inner nuclear and outer plexiform, and to a lesser extent the outer nuclear layer. Cell targets were ganglion cells, bipolar cells, Müller cells, and photoreceptors. Exo-AAV2 serves as a robust gene delivery tool for murine retina, and the simplicity of production and isolation should make it widely applicable to basic research of the eye.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Exo-AAV had improved ability to cross the inner limiting membrane of the retina after intravitreal injection in mice (146).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [146]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Routes and mechanisms of extracellular vesicle uptake
Mulcahy, L. A., Pink, R. C., & Carter, D. R. F. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.24641 · Cited by 2,832
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles
György, B., Szabó, T. G., Pásztói, M., Pál, Z., Misják, P., Aradi, B., László, V., Pállinger, É., Pap, E., Kittel, Á., et al. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0689-3 · Cited by 2,074
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Yang, T., Martin, P., Fogarty, B., Brown, A., Schurman, K., Phipps, R., Yin, V. P., Lockman, P., & Bai, S. (2015) · Pharmaceutical Research · doi:10.1007/s11095-014-1593-y · Cited by 975 · cited 1×
“Since exosomes can cross the blood brain barrier 17,18 , and we have shown exo-AAV to cross an endothelial barrier 16 , we hypothesized that exosomes might also facilitate penetration of AAV vectors across other barriers, such as between the vitreous and the retina.”
Christianson, H. C., Svensson, K. J., van Kuppevelt, T. H., Li, J.-P., & Belting, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304266110 · Cited by 903 · cited 1×
“Our group and others have shown extracellular vesicles to be heparin sensitive in their ability to enter cells 22–24 .”
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Dalkara, D., Byrne, L. C., Klimczak, R. R., Visel, M., Yin, L., Merigan, W. H., Flannery, J. G., & Schaffer, D. V. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005708 · Cited by 734
A pathogenic picornavirus acquires an envelope by hijacking cellular membranes
Feng, Z., Hensley, L., McKnight, K. L., Hu, F., Madden, V., Ping, L., Jeong, S.-H., Walker, C., Lanford, R. E., & Lemon, S. M. (2013) · Nature · doi:10.1038/nature12029 · Cited by 713
Cited by
Exosome-Mediated Metastasis: Communication from a Distance
Wortzel, I., Dror, S., Kenific, C. M., & Lyden, D. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.011 · Cited by 1,285
Extracellular vesicles: novel promising delivery systems for therapy of brain diseases.
Rufino-Ramos, D., Albuquerque, P. R., Carmona, V., Perfeito, R., Nobre, R. J., & Pereira de Almeida, L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.001 · Cited by 418
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality
Hudry, E., & Vandenberghe, L. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.017 · Cited by 369
Self-citationAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
“169 An intratumoral administration of AAV6 vexosomes carrying a suicide gene in a murine xenograft model revealed a 2.3-fold increase in hepatocellular carcinoma regression compared with untreated animals.”
BackgroundInfluentialVarious AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
Pre-metastatic niche: formation, characteristics and therapeutic implication
Wang, Y., Jia, J., Wang, F., Fang, Y., Yang, Y., Zhou, Q., Yuan, W., Gu, X., Hu, J., & Yang, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01937-7 · Cited by 246
“418 However, exosomes derived from immune cells in vivo are only capable of serving as drug delivery vehicles and do not produce suf fi cient effects to inhibit tumor progression.”
BackgroundExosome-mediated delivery of gene vectors for gene therapy
Duan, L., Xu, L., Xu, X., Qin, Z., Zhou, X., Xiao, Y., Liang, Y., & Xia, J. (2021) · Nanoscale · doi:10.1039/d0nr07622h · Cited by 238
A comprehensive review of challenges and advances in exosome-based drug delivery systems
Palakurthi, S. S., Shah, B., Kapre, S., Charbe, N., Immanuel, S., Pasham, S., Thalla, M., Jain, A., & Palakurthi, S. (2024) · Nanoscale Advances · doi:10.1039/d4na00501e · Cited by 215
Targeted delivery of therapeutic agents to the heart
Sahoo, S., Kariya, T., & Ishikawa, K. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00499-9 · Cited by 159
Exosome-mediated delivery of RNA and DNA for gene therapy
Munagala, R., Aqil, F., Jeyabalan, J., Kandimalla, R., Wallen, M., Tyagi, N., Wilcher, S. A., Yan, J., Schultz, D. J., Spencer, W. A., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.011 · Cited by 153
Extracellular vesicles: mediators and biomarkers of pathology along CNS barriers
Ramirez, S. H., Andrews, A. M., Paul, D., & Pachter, J. S. (2018) · Fluids and Barriers of the CNS · doi:10.1186/s12987-018-0104-7 · Cited by 128
“The latest novel utilization of EVs as delivery vehicles includes the encapsulation of AAV gene therapy vectors (vexosomes) for the treatment of CNS diseases [162, 163].”
BackgroundRoles of Exosomes in Ocular Diseases
Liu, J., Jiang, F., Jiang, Y., Wang, Y., Li, Z., Shi, X., Zhu, Y., Wang, H., & Zhang, Z. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s277190 · Cited by 139
“Comparison of intravitreal injection of traditional AAV2 with the novel exosome-associated AAV2 (exo-AAV2) revealed that exo-AAV2 carrying the GFP-coding gene adeno-associated virus (AAV) was more strongly expressed and had greater penetrability in the retina.(123) Additionally, when exosomes from MSCs overexpress miR…”
BackgroundMeliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127
Self-citationExosome-mediated delivery of an anti-angiogenic peptide inhibits pathological retinal angiogenesis
Dong, X., Yi, L., Yu, Z., Wang, T., Liu, Y., Han, G., Zhang, X., Li, Y., Song, Y., Xu, H., et al. (2021) · Theranostics · doi:10.7150/thno.54755 · Cited by 131
“In the retina, EXO-associated AAV vectors have shown robust delivery efficiency into the murine retina compared with conventional AAV [29].”
BackgroundA concise review on cancer treatment methods and delivery systems
Bidram, E., Esmaeili, Y., Ranji‐Burachaloo, H., Al-Zaubai, N., Zarrabi, A., Stewart, A. G., & Dunstan, D. E. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101350 · Cited by 140
Extracellular vesicles as delivery systems at nano-/micro-scale
Fu, P., Zhang, J., Li, H., Mak, M., Xu, W., & Tao, Z. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113910 · Cited by 127
Stanimirovic, D. B., Sandhu, J. K., & Costain, W. J. (2018) · BioDrugs · doi:10.1007/s40259-018-0309-y · Cited by 115
Jarrige, M., Frank, E., Herardot, E., Martineau, S., Darle, A., Benabidès, M., Domingues, S., Chose, O., Habeler, W., Lorant, J., et al. (2021) · Cells · doi:10.3390/cells10020240 · Cited by 116
“However, these sheets tend to form rosettes and PRs are transplanted with other cell types present in organoids, which limits the number of connections with the other neurons present in the retina.”
BackgroundInfluentialRecent advances of exosomes in immune-mediated eye diseases
Li, N., Zhao, L., Wei, Y., Ea, V. L., Nian, H., & Wei, R. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1372-0 · Cited by 104
Exosome-based small RNA delivery: Progress and prospects
Lu, M., Xing, H., Xun, Z., Yang, T., Ding, P., Cai, C., Wang, D., & Zhao, X. (2018) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2017.07.008 · Cited by 97
“[80], packaged AAV2 into exosomes and formed exosome-associated AAV2 vector (called vexosomes).”
BackgroundLi, X., Salvia, S. L., Liang, Y., Adamiak, M., Kohlbrenner, E., Jeong, D., Chepurko, E., Ceholski, D. K., López-Gordo, E., Yoon, S., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063759 · Cited by 96
Soltanmohammadi, F., Gharehbaba, A. M., Zangi, A. R., Adibkia, K., & Javadzadeh, Y. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117248 · Cited by 94
Mouse γ-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Qizhao, W., Zhuang, P., Huang, H., Li, L., Liu, L., Webber, H. C., Dalal, R., Siew, L., Fligor, C. M., Chang, K., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0102-20.2020 · Cited by 89
“To determine the GFP intensity on fundus images, the fluorescence intensity to radius measurement with the center at the optic disk was obtained by ImageJ and the Concentric Circles Plugin as described before (Wassmer et al., 2017).”
MethodRetinitis Pigmentosa: Novel Therapeutic Targets and Drug Development
Wu, K. Y., Kulbay, M., Toameh, D., Xu, A. Q., Kalevar, A., & Tran, S. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020685 · Cited by 90
Sahel, D. K., Vora, L. K., Saraswat, A. L., Sharma, S., Monpara, J. D., D’souza, A. A., Mishra, D., Tryphena, K. P., Kawakita, S., Khan, S. U., et al. (2023) · Advanced Science · doi:10.1002/advs.202207512 · Cited by 88
Nieuwenhuis, B., Laperrousaz, E., Tribble, J. R., Verhaagen, J., Fawcett, J. W., Martin, K. R. G., Williams, P. A., & Osborne, A. (2023) · Gene Therapy · doi:10.1038/s41434-022-00380-z · Cited by 88
Selective drug delivery to the retinal cells: Biological barriers and avenues
Ramsay, E., Lajunen, T., Bhattacharya, M., Reinisalo, M., Rilla, K. J., Kidron, H., Terasaki, T., & Urtti, A. O. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.028 · Cited by 83
Li, L., Huang, H., Fang, F., Liu, L., Sun, Y., & Hu, Y. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00109 · Cited by 76
Tang, Z., Fan, X., Chen, Y., & Gu, P. (2022) · Advanced Science · doi:10.1002/advs.202003699 · Cited by 95
Emerging approaches for restoration of hearing and vision
Kleinlogel, S., Vogl, C., Jeschke, M., Neef, J., & Moser, T. (2020) · Physiological Reviews · doi:10.1152/physrev.00035.2019 · Cited by 91
Schiera, G., Liegro, C. M. D., & Liegro, I. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010266 · Cited by 73
“EVs have been also successfully used to mediate adeno-associated virus (AAV)-driven gene delivery into the murine retina [296].”
MethodThe future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“…barriers, resistance to neutralizing antibodies Mouse High transduction of ganglion and bipolar cells, lower transduction of photoreceptors Wassmer et al. (2017) AAV: Adeno associated virus; HS: heparan sulfate; IVT: intravitreal; RP: retinitis pigmentosa; RPE: retinal pigment epithelium;…”
BackgroundInfluentialAdvances in development of exosomes for ophthalmic therapeutics
Tian, Y., Zhang, T., Li, J., & Tao, Y. K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114899 · Cited by 67
Extracellular Vesicles: Biomarkers, Therapeutics, and Vehicles in the Visual System
van der Merwe, Y., & Steketee, M. B. (2017) · Current Ophthalmology Reports · doi:10.1007/s40135-017-0153-0 · Cited by 64
Enhanced production of exosome-associated AAV by overexpression of the tetraspanin CD9
Schiller, L. T., Lemus-Diaz, N., Rinaldi Ferreira, R., Böker, K. O., & Gruber, J. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.008 · Cited by 63
Zhang, K. Y., & Johnson, T. V. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108545 · Cited by 73
Gross, D., Tedesco, N., Leborgne, C., & Ronzitti, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.857276 · Cited by 65
Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy
Zwi‐Dantsis, L., Mohamed, S., Massaro, G., & Moeendarbary, E. (2025) · Viruses · doi:10.3390/v17020239 · Cited by 76
“…its affinity for heparan sulfate, is the most studied among all AAVs and utilized in research and clinical trials [40], showing a broad tissue tropism, including for renal tissue [41,42], hepatocytes [43,44], the retina [45,46], the central nervous system (CNS) [47,48], and skeletal muscles [40].”
Extracellular vesicles provide a capsid‐free vector for oncolytic adenoviral DNA delivery
Saari, H., Turunen, T. A., Lõhmus, A., Turunen, M. P., Jalasvuori, M., Butcher, S. J., Ylä‐Herttuala, S., Viitala, T., Cerullo, V., Siljander, P. R. M., et al. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2020.1747206 · Cited by 65
“treatment of cancer [23,35] and that IEVs carrying adeno-associated viruses (AAV) may serve as enhanced tools for gene therapy [24,36,37].”
Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Khatib, T. Z., & Martin, K. R. G. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1663385 · Cited by 61
Lugin, M. L., Lee, R. T., & Kwon, Y. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c03850 · Cited by 63
Peynshaert, K., Devoldere, J., Forster, V., Picaud, S. A., Vanhove, C., Smedt, S. C. D., & Remaut, K. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1375578 · Cited by 64
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“Exo-AAV had improved ability to cross the inner limiting membrane of the retina after intravitreal injection in mice (146).”
BackgroundDevelopment of New Strategies Using Extracellular Vesicles Loaded with Exogenous Nucleic Acid
Orefice, N. S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12080705 · Cited by 59
Wagner, H. J., Weber, W., & Fussenegger, M. (2021) · Advanced Science · doi:10.1002/advs.202004018 · Cited by 54
Exosomes, extracellular vesicles and the eye
Rudraprasad, D., Rawat, A., & Joseph, J. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108892 · Cited by 51
Orefice, N. S., Souchet, B., Braudeau, J., Alves, S., Piguet, F., Collaud, F., Ronzitti, G., Tada, S., Hantraye, P., Mingozzi, F., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.06.005 · Cited by 48
AAV-Containing Exosomes as a Novel Vector for Improved Gene Delivery to Lung Cancer Cells
Liu, B., Li, Z., Huang, S. W., Yan, B., He, S., Chen, F., & Liang, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.707607 · Cited by 54
“, 2020), retina (Wassmer et al., 2017), cochlea (György et al.”
Delivering AAV to the Central Nervous and Sensory Systems
Peters, C. W., Maguire, C. A., & Hanlon, K. S. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.004 · Cited by 45
Self-citationHu, M., Han, Y., Zhang, X., Tian, S., Shang, Z., Yuan, Z., & He, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07077-y · Cited by 61
“It can readily penetrate both the inner nuclear and outside plexiform structures [104].”
Recent Advances in the Use of Exosomes in Sjögren’s Syndrome
Huang, Y., Li, R., Ye, S., Lin, S., Yin, G., & Xie, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01509 · Cited by 49
Exosomes: Structure, Biogenesis, Types and Application in Diagnosis and Gene and Drug Delivery
Agarwal, S., Agarwal, V., Agarwal, M., & Singh, M. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200731011702 · Cited by 47
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
“68–71 A recent study demonstrated the stabilizing effects of tetraspanin CD9 in increasing exosome production.”
Emerging Role of Exosomes in Retinal Diseases
Zhang, Z., Mugisha, A., Fransisca, S., Liu, Q., Xie, P., & Hu, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.643680 · Cited by 53
“Compared with intravitreal injection of traditional adeno-associated virus 2 (AAV2), the novel exosome-associated AAV2 (exo-AAV2) revealed that exo-AAV2 carrying the GFPcoding gene AAV was more strongly expressed and had greater penetrability in the retina (Wassmer et al., 2017).”
BackgroundVerma, N., Arora, S., Singh, A. K., & Ahmed, J. (2025) · RSC Pharmaceutics · doi:10.1039/d5pm00097a · Cited by 47
Emerging gene therapies for cystic fibrosis
Miah, K. M., Hyde, S. C., & Gill, D. R. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1634547 · Cited by 48
György, B., & Maguire, C. A. (2017) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1488 · Cited by 46
“bipolar cells (Figure 5(d)) and photoreceptor cells.(42) In aggregate, these data support the use of exo-AAV2 for efficient genetic modification of murine retina for basic research applications as well as consideration for further preclinical development (Box 1).”
ResultSelf-citationUse of exosomes as vectors to carry advanced therapies
Sancho‐Albero, M., Medel-Martínez, A., & Martín‐Duque, P. (2020) · RSC Advances · doi:10.1039/d0ra02414g · Cited by 43
Azparren‐Angulo, M., Royo, F., González, E., Patricio-Liébana, M., Brotons, B., Berganza, J., Goñi‐de‐Cerio, F., Manicardi, N., Abad‐Jordà, L., Gracia‐Sancho, J., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107683 · Cited by 49
The Emerging Role of Topical Ocular Drugs to Target the Posterior Eye
Wang, L., Zhou, M., & Zhang, H. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00365-y · Cited by 43
Zou, T., Zhang, J., Liu, Y., Zhang, Y., Sugimoto, K., & Mei, C. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00131 · Cited by 37
Extracellular Vesicles in the Cornea: Insights from Other Tissues
McKay, T. B., Yeung, V., Hutcheon, A. E. K., Guo, X., Zieske, J. D., & Ciolino, J. B. (2021) · Analytical Cellular Pathology · doi:10.1155/2021/9983900 · Cited by 37
“One study reported that EV-associated adenoassociated virus type 2 (EV-AAV-2) from 293 T cells demonstrated deeper penetration via intravitreal injection in the retina, efficiently reaching the inner and outer plexiform compared to conventional AAV-2, thereby suggesting that this treatment may be an effective method f…”
MethodCheng, M. L., Dietz, L., Gong, Y., Eichler, F., Nammour, J., Ng, C., Grimm, D., & Maguire, C. A. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.122 · Cited by 36
“In subsequent studies, we showed that EV-associated AAV vectors, which we call exo-AAV, can enhance transduction of target cells in vivo , 6,7 and also evade neutralizing antibodies, 6,8 two clinically relevant features.”
Self-citationAdeno‐associated virus‐based Alzheimer's disease mouse models and potential new therapeutic avenues
Ittner, L. M., Klugmann, M., & Ke, Y. D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14637 · Cited by 38
Viral vectors for gene delivery to the inner ear
Maguire, C. A., & Corey, D. P. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107927 · Cited by 34
Self-citationToward the Optical Cochlear Implant
Dombrowski, T., Rankovic, V., & Moser, T. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a033225 · Cited by 35
“…Harb Perspect Med doi: 10.1101/cshperspect.a033225 w w w .p er sp ec ti ve si n m ed ic in e. o rg were successfully used for gene delivery into the murine retina (Wassmer et al. 2017) and into the murine inner ear to partially rescue hearing in a hereditary deafness model (György et al. 2017).”
MethodInfluentialZhou, X., Liu, J., Xiao, S., Liang, X., Li, Y., Mo, F., Xin, X., Yang, Y., & Gao, C. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s459905 · Cited by 34
Cationic-motif-modified exosomes for mRNA delivery to retinal photoreceptors
Cotto, H. A. M., Pathrikar, T. V., Hakim, B., Baby, H. M., Zhang, H., Zhao, P., Ansaripour, R., Amini, R., Carrier, R. L., & Bajpayee, A. G. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00849a · Cited by 33
AAV6 Vexosomes Mediate Robust Suicide Gene Delivery in a Murine Model of Hepatocellular Carcinoma
Khan, N., Maurya, S., Bammidi, S., & Jayandharan, G. R. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.006 · Cited by 33
“The efficacy AAV2- based vexosomes with enhanced transduction of the retinal cells upon intravitreal delivery has been known.(19) Other studies that have employed vexosomes derived from AAV serotypes, such as AAV1, -6, -7, -8, or -9, have mostly analyzed the rate of formation and distribution of vectors in the cell ly…”
Virus vector-mediated genetic modification of brain tumor stromal cells after intravenous delivery
Volak, A., LeRoy, S. G., Natasan, J.-S., Park, D. J., Cheah, P.-S., Maus, A., Fitzpatrick, Z., Hudry, E., Pinkham, K., Gandhi, S., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2889-2 · Cited by 33
“We utilized exo-AAV in this study has we have previously shown that this vector system has attributes such as enhanced transduction to CNS [21], liver [31], inner ear [32], and retina [33] compared to conventional AAV.”
Self-citationIn vivo engineering of lymphocytes after systemic exosome-associated AAV delivery
Breuer, C. B., Hanlon, K. S., Natasan, J.-S., Volak, A., Meliani, A., Mingozzi, F., Kleinstiver, B. P., Moon, J. J., & Maguire, C. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-61518-w · Cited by 32
Self-citationRelease of VAMP5‐positive extracellular vesicles by retinal Müller glia in vivo
Demais, V., Pohl, A., Wunderlich, K. A., Pfaller, A. M., Kaplan, L., Barthelemy, A., Dittrich, R., Puig, B., Giebel, B., Hauck, S. M., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12254 · Cited by 31
“In fact, Müller cells have been mainly studied as target of EVs (Didiano et al., 2020; Eastlake et al., 2021; Kamalden et al., 2017; Ke et al., 2021; Peng et al., 2018; Wassmer et al., 2017; Zhang et al., 2020).”
BackgroundYu, J., Yin, Y., Leng, Y., Zhang, J., Wang, C., Chen, Y., Li, X., Wang, X., Liu, H., Liao, Y., et al. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114842 · Cited by 31
AAV2-Mediated Transduction of the Mouse Retina After Optic Nerve Injury
Nickells, R., Schmitt, H., Maes, M. E., & Schlamp, C. L. (2017) · Investigative Ophthalmology and Visual Science · doi:10.1167/iovs.17-22634 · Cited by 29
Fatigue life prediction of aluminum alloy 6061 based on defects analysis
Chen, H., Yang, Y., Cao, S., Gao, K. Y., Xu, S., Li, Y., & Zhang, R. (2021) · International Journal of Fatigue · doi:10.1016/j.ijfatigue.2021.106189 · Cited by 28
Wang, W., Liu, J., Yang, M., Qiu, R., Li, Y., Bian, S., Hao, B., & Lei, B. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.328 · Cited by 30
“Furthermore, since exosomes are able to cross the blood–brain barrier and the blood–retina barrier, 14,15 exo-AAV vectors have the potential to enhance therapeutic effects by improving transduction efficiencies in the retinal and other neural tissues.”
Exosomes in the pathogenesis and treatment of ocular diseases
Zhang, Z., Liang, X., Zhou, J., Meng, M., Gao, Y., Yi, G., & Fu, M. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108626 · Cited by 35
Exosome-based crosstalk in glaucoma pathogenesis: a focus on oxidative stress and neuroinflammation
Wang, L., & Wei, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202704 · Cited by 30
“When injected into the mice’s vitreous cavity, exosomes can efficiently reach the inner nuclear layer and outer plexiform layer, and to a lesser extent the outer nuclear layer as well (129).”
BackgroundRunning to save sight: The effects of exercise on retinal health and function
Chu‐Tan, J. A., Kirkby, M., & Natoli, R. (2021) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14023 · Cited by 34
Extracellular Vesicles as Novel Drug-Delivery Systems through Intracellular Communications
Matsuzaka, Y., & Yashiro, R. (2022) · Membranes · doi:10.3390/membranes12060550 · Cited by 29
Research status and future prospects of extracellular vesicles in primary Sjögren’s syndrome
Zhao, J., An, Q., Zhu, X., Yang, B., Gao, X., Niu, Y., Zhang, L., Xu, K., & Ma, D. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02912-1 · Cited by 26
“Until now, studies on exosomes of pSS have mainly focused on saliva and tears [53].”
BackgroundExtracellular vesicles: an emerging player in retinal homeostasis
Chatterjee, A., & Singh, R. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1059141 · Cited by 29
“Exosomeassociated AAV2 vectors outperformed conventional AAV2 in retinal transduction after intravitreal injection and were able to transduce a high number of bipolar cells, and also some photoreceptors (Wassmer et al., 2017).”
BackgroundMaurya, S., & Jayandharan, G. R. (2020) · Virus Research · doi:10.1016/j.virusres.2020.197966 · Cited by 23
Shiozawa, A. L., Igarashi, T., Kobayashi, M., Nakamoto, K., Kameya, S., Fujishita, S., Takahashi, H., & Okada, T. (2020) · Molecular vision · Cited by 25
The Roles of Exosomes in Visual and Auditory Systems
Jiang, P., Zhang, S., Cheng, C., Gao, S., Tang, M., Lü, L., Yang, G., & Chai, R. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00525 · Cited by 24
Kwak, G., Gololobova, O. A., Sharma, N., Caine, C., Mazur, M., Mulka, K. R., West, N. E., Solomon, G. M., Cutting, G. R., Witwer, K. W., et al. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12324 · Cited by 22
“However, we and other demonstrated with TEM that multiple AAV capsids were associated with individual EVs (Maguire et al., 2012; Maurya & Jayandharan, 2020; Wassmer et al., 2017).”
BackgroundResultInfluentialKwon, J., Schumacher, S. M., Gao, E., Chuprun, J. K., Ibetti, J., Roy, R., Khan, M., Kishore, R., & Koch, W. J. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00571.2020 · Cited by 20
Utilizing extracellular vesicles as a drug delivery system in glaucoma and RGC degeneration
Durmaz, E., Dribika, L., Kutnyanszky, M., & Mead, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.029 · Cited by 23
“Additionally, hybrid systems by intravitreal injection were tested for retinal degeneration, such as the combination of AAV and EV that demonstrated deeper penetration in the retina than conventional AVV gene delivery [109].”
Spokeviciute, B., Kholia, S., & Brizzi, M. F. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107352 · Cited by 23
Rational design of extracellular vesicles for targeted drug delivery across physiological barriers
Baby, H. M., Zhang, H., Selvadoss, A., Pathrikar, T. V., & Bajpayee, A. G. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102920 · Cited by 24
Recent theranostic paradigms for the management of Age-related macular degeneration
Suri, R., Neupane, Y. R., Jain, G. K., & Kohli, K. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105489 · Cited by 21
Advances in Recombinant Adeno-Associated Virus Vectors for Neurodegenerative Diseases
Li, L., Vasan, L., Kartono, B., Clifford, K. P., Attarpour, A., Sharma, R., Mandrozos, M., Kim, A., Zhao, W., Belotserkovsky, A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102725 · Cited by 20
Goodwin, M. S., Croft, C. L., Futch, H. S., Ryu, D. H., Ceballos‐Diaz, C., Liu, X., Paterno, G., Mejia, C., Deng, D. Z., Menezes, K., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00361-z · Cited by 20
Non-Viral Delivery of Gene Therapy to the Tendon
Jin, J., Yang, Q., & Zhou, Y. L. (2022) · Polymers · doi:10.3390/polym14163338 · Cited by 21
Shen, J., Xiao, R., Bair, J. A., Wang, F., Vandenberghe, L. H., Dartt, D. A., Baranov, P. Y., & Ng, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1049-0 · Cited by 19
Self-citationExtracellular vesicles in the retina - putative roles in physiology and disease
Kalargyrou, A. A., Guilfoyle, S. E., Smith, A. J., Ali, R. R., & Pearson, R. A. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1042469 · Cited by 22
Tear fluid derived extracellular vesicles for new biomarker discovery
Phan, N., Li, Y., Yang, M., & Liu, F. (2025) · The Ocular Surface · doi:10.1016/j.jtos.2025.05.001 · Cited by 16
Habibi, A., Zarei‐Behjani, Z., Falamarzi, K., Malekpour, M., Ebrahimi, F., Soleimani, M., Nejabat, M., Khosravi, A., Moayedfard, Z., Pakbaz, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1097456 · Cited by 18
Challenges in AAV-Based Retinal Gene Therapies and the Role of Magnetic Nanoparticle Platforms
Siontas, O., & Ahn, S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237385 · Cited by 13
“However, as previously discussed, exosome-mediated IVI delivery of AAVs has so far been studied only in rodent eyes, which differ significantly from human eyes [118,119].”
Wu, F., He, W., Xiao, Y., Wu, Q., Zhang, Q., Zhang, T., Xu, L., & Pang, X. (2025) · Advanced Science · doi:10.1002/advs.202408397 · Cited by 17
Metadata
- Authors
- Wassmer, S. J., Carvalho, L. S., György, B., Vandenberghe, L. H., & Maguire, C. A.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- Howard Hughes Medical Institute (US)
- Harvard University (US)
- Corresponding author
- György, Bence
- Vandenberghe, Luk H.
- Maguire, Casey A.
- Venue
- Scientific Reports
- Published
- 2017-03-31
- Volume
- 7
- Issue
- 1
- Pages
- 45329-45329
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5374486
- OpenAlex
- W2601308787
- Cited by
- 164
- References
- 46
- Citations by year
- 2026: 10 · 2025: 25 · 2024: 17 · 2023: 22 · 2022: 13 · 2021: 23 · 2020: 26 · 2019: 11 · 2018: 8 · 2017: 8
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
- Funders
- Cure Alzheimer's Fund
- Grousbeck Family Foundation
- National Institutes of Health
- National Eye Institute (DP1EY023177)
- National Institute of Neurological Disorders and Stroke (P30NS045776)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus type 2, retinal gene delivery, intravitreal injection, exosomes, GFP expression, retinal cell types, Müller cells, photoreceptors
- MeSH terms
- Dependovirus, Animals, Genetic Vectors, Male, Retina, Gene Transfer Techniques, Green Fluorescent Proteins, Mice, Exosomes, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.